Latest news with #AuroraCannabisInc
Associated Press
26-06-2025
- Business
- Associated Press
Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program
Canada's Largest Medical Cannabis Company Offers the Country's Most Inclusive Medical Cannabis Pricing Program NASDAQ | TSX: ACB EDMONTON, AB, June 26, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 CAD for Aurora patients through 'As over half of the country's adult population fits within this income threshold, our compassionate pricing program represents the most accessible, inclusive pricing plan to access medical cannabis in Canada,' says Geoff Hoover, SVP of Canadian Commercial at Aurora. 'We're committed to breaking down barriers to access high quality medical cannabis, and this change empowers more patients to explore different treatment options at pricing they can afford.' The changes to the compassionate pricing program are available alongside new medical cannabis products, including: In addition to the compassionate pricing program, Aurora offers resources to seniors, pediatric patients, veterans, first responders, and others seeking care through medical cannabis. Patients can visit for more information and to connect with the Aurora client care team for further support. About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol 'ACB'. Forward Looking Information This news release includes statements containing certain 'forward-looking information' within the meaning of applicable securities law ('forward-looking statements'). Forward-looking statements are frequently characterized by words such as 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company's expanded compassionate pricing program, and associated benefits for patients. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading 'Risk Factors' in the Company's annual information form dated June 17, 2025 (the 'AIF') and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc.
Cision Canada
24-06-2025
- Business
- Cision Canada
Aurora Sets New Standard in Poland with the Launch of Two High Potency Flower Products
Proprietary Genetics to be the Highest Potency Medical Cannabis Products Available on the Market NASDAQ| TSX: ACB EDMONTON, AB, June 24, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces today the launch of two new proprietary cultivars in Poland, marking the highest potency medical cannabis products available in the country. Grown and manufactured in the company's Canadian GACP and EU-GMP facilities, the premium dried medical cannabis products Farm Gas and Sourdough are crafted with precision and expertise to deliver a superior, high THC flower. "As a result of our cutting-edge genetic breeding program, we're best positioned to introduce these tried-and-true proprietary cultivars into the Polish market with assurance in quality and excellence," says Michael Simon, VP of Commercial at Aurora Europe. "We recognize that prescribers are looking for high-quality, high potency medical cannabis products for their patients, and we're proud to offer superior products with proven success in the Canadian market." The first cultivar available on June 30 for prescription is Farm Gas, followed by Sourdough which will be available in early August. These speciality dried flowers are hang-dried, hand finished and have unique and favourable properties including: Farm Gas | 27% THC, <1% CBD, bred from Sour Diesel and GMO genetics. This cultivar has a terpene profile of limonene, caryophyllene, nerolidol, and an aroma profile that features notes of kerosene, diesel, and gas with a slight chem taste, followed by a slightly sweet finish with fruit sherbet undertones. Sourdough | 29% THC, <1% CBD, bred from Cake and Diesel genetics. This cultivar has a terpene profile of limonene, caryophyllene, myrcene, and an aroma profile that carries sour, cake, and gasoline notes. Aurora remains steadfast in our international leadership, leveraging the company's unrivaled focus on science and innovation to fuel global advancements. With extensive knowledge of Europe's intricate regulatory landscape and proven expertise in cultivation, Aurora stands as the trusted leader in advancing the Polish medical cannabis market. About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch and availability of the Company's new high-potency flower products in Poland, as well as statements regarding the Company's international leadership and continued focus on science and innovation to fuel global advancements. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. SOURCE Aurora Cannabis Inc.
Yahoo
18-06-2025
- Business
- Yahoo
Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -36.36%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced earnings of $0.06, delivering a surprise of 50%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Aurora Cannabis , which belongs to the Zacks Medical - Products industry, posted revenues of $63.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.65%. This compares to year-ago revenues of $49.98 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Aurora Cannabis shares have added about 38.4% since the beginning of the year versus the S&P 500's gain of 1.7%. While Aurora Cannabis has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Aurora Cannabis: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.17 on $69.13 million in revenues for the coming quarter and $0.44 on $268.33 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Abbott (ABT), has yet to report results for the quarter ended June 2025. This maker of infant formula, medical devices and drugs is expected to post quarterly earnings of $1.25 per share in its upcoming report, which represents a year-over-year change of +9.7%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. Abbott's revenues are expected to be $11.05 billion, up 6.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
07-05-2025
- Business
- Yahoo
Higher Returns with Aurora Cannabis
By Rayk Riechmann Investors want what they're on! Aurora Cannabis Inc. (Nasdaq: ACB), a federally-licensed producer of medical and consumer cannabis, is attractively positioned as an early leader in global regulated markets. ACB leverages a best-in-class brand portfolio to grow and sell products across all major cannabis categories. And it's translating to results: the company just delivered a top-down beat on strengthening industry tailwinds and expanding global sales. With a strong footprint in key medical cannabis markets in North America, Europe, and Australia, the company excels at meeting both patient and regulatory demands. This early adaptation of medical markets is already paying off with strong revenue growth and creates a first-mover advantage once these regions transform into recreational markets. Germany is close to creating a national legalized consumer market, and as other European nations follow suit, top-line growth could skyrocket. ACB is strategically positioned to rapidly expand into new markets within Europe as regulatory liberalization continues. Notably, a local presence in these markets mostly shields ACB from tariff-related uncertainty. Here's ACB's global presence in one glance: #1 in Canadian medical market share, #2 in Australia following the acquisition of MedReleaf Australia in 2024, #3 in Poland, and one of only three companies licensed to cultivate in Germany. Since June 2021, ACB has introduced 24 new proprietary strains, which drive yield, potency, and cost-efficiency. Newly engineered next-gen cultivars appeal to consumers with increased consistency and save up to 30% in per-unit costs. Both are key differentiators in the consumer and medical market. ACB's one-of-a-kind combination of regulatory expertise, brand architecture, and scientific innovation enables superior financial performance, as demonstrated in the top-down beat delivered in the latest quarter, driven mainly by a 51% increase in international medical cannabis revenue. The debt-free cannabis business has taken decisive steps to ensure profitable growth moving forward. By rightsizing its SG&A expenses and consolidating its manufacturing footprint, ACB delivered positive net-income for the second time in company history, as well as record adjusted EBITDA and FCF. Our bullish outlook for 2025 is fueled by improved company profitability and favorable external forces. ACB currently trades at a NTM price/sales multiple of 0.96x – a big discount to its own 3-year mean multiple of 1.51x, indicating that the stock price has not caught up to recent developments and is due for a rerating. What's more, ACB trades at a significant discount to almost all peers on an Ebitda basis.
Yahoo
02-05-2025
- Business
- Yahoo
Is Aurora Cannabis Inc. (ACB) Among the Best Tobacco and Cigarette Stocks to Buy Now?
We recently compiled a list of the 10 Best Tobacco and Cigarette Stocks to Buy Now. In this article, we are going to take a look at where Aurora Cannabis Inc. (NASDAQ:ACB) stands against the other Tobacco and Cigarette stocks. Cigarette and tobacco stocks are companies that produce and sell cigars, snuff, chewing tobacco, cigarettes, e-cigarettes, and all other tobacco products. The tobacco industry has long been a huge winner for investors. Tobacco companies were among the top performers during the 20th century because of their reputation for providing investors with substantial dividend yields as well as their addictive, extremely profitable, and recession-proof product. However, tobacco firms now confront a different set of challenges. Globally, smoking rates have been progressively declining, particularly in the United States, as a result of growing legislation and health concerns. The industry has attempted to shift to next-generation products as a result. Some people believe that e-cigarettes, vaporizers, and chewable nicotine pouches are healthier options since they avoid some of the negative aspects of smoking cigarettes, such as unpleasant odors. Some companies are expanding beyond tobacco, working with cannabis businesses to capitalize on the potential development in a market that shares numerous similarities with tobacco. There are other hazards associated with tobacco stocks, such as heightened regulation and a decline in smoking rates. According to the Centers for Disease Control and Prevention, the number of tobacco farms in the United States decreased from 93,530 in 1997 to roughly 3,000 in 2022. Nonetheless, the USA was the world's fifth-largest producer of tobacco in 2021, harvesting 431.6 million pounds in 2022, compared to 1.74 billion pounds in 1997. Seventy-seven percent of U.S. production came from North Carolina or Kentucky. Price reductions accounted for $5.7 billion (72%) of the $8.6 billion tobacco businesses spent on advertising in 2022, which included $572.7 million for smokeless tobacco and $8.01 billion for cigarettes. Marketing costs for e-cigarettes came to $859.4 million in 2021. Sales of cigarette packs fell from 12.5 billion to 9.1 billion packs between 2015 and 2021, a 27% decrease. In 2024, the average cigarette tax in each state was $1.93, while the federal tax was $1.01. Despite the industry's weak revenue and profit development, investors continue to be drawn to these stocks due to their consistent dividends, profitability, and solid profit margins. Investors believe that stronger growth will eventually be catalyzed by next-generation products. However, on April 2, 2025, the U.S. Supreme Court upheld the FDA's decision to deny approval for flavored e-cigarettes in a major decision. According to Justice Samuel Alito, vape producers were given 'adequate notice' of the FDA's review criteria. In this case, businesses like Vapetasia and Triton Distribution applied for certification for products such as 'Mother's Milk and Cookies' and 'Killer Kustard Blueberry.' The FDA has been regulating vaping products since 2016, claiming that flavored vapes represent a health concern and may encourage young people to use tobacco. More than 2.1 million youths in the US reported using e-cigarettes in 2023, with 10% of high school students vaping. The FDA has rejected thousands of flavored products and has only approved tobacco and menthol flavors. One specific issue, marketing plan consideration, was returned to lower courts after the Supreme Court reversed the 5th Circuit's prior criticism of the FDA's changing criteria. Companies that promote unapproved products risk 'civil and criminal penalties,' the FDA warned. A modern cannabis retail store with a wide selection of products and vaporizers. For this article, we sifted through the online rankings to form an initial list of the 15 Tobacco and Cigarette Stocks. We have also included e-cigarette and cannabis companies. From the resultant dataset, we chose 10 stocks with the highest number of hedge fund investors, using Insider Monkey's database of 1009 hedge funds in Q4 2024 to gauge hedge fund sentiment for stocks. We have used the stock's market cap as of April 25, 2025, as a tie-breaker in case two or more stocks have the same number of hedge funds invested. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here). Number of Hedge Fund Holders: 6 Aurora Cannabis Inc. (NASDAQ:ACB), a Canadian company with its headquarters located in Edmonton, grows and markets cannabis for both medical and recreational purposes under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company is largely based in Canada, it has expanded globally through medical cannabis export agreements. It is one of the Best Tobacco Stocks. The third quarter of 2025 was a strong period for Aurora Cannabis Inc. (NASDAQ:ACB), as its earnings per share of $0.41 greatly exceeded forecasts by $0.42. The business produced a record adjusted EBITDA of $23.1 million, up 316% YoY, and a record net income of $31.2 million, up 282% YoY. Furthermore, Q3 revenue exceeded projections by 28.73% YoY to $61.62 million, led by record-breaking global medical net revenue. The company's globalization plan is working; its overseas sales climbed by 112% in the medical cannabis industry. International revenue outpaced Canadian medicinal cannabis for the second consecutive quarter. In 2025, ACB also produced $27.4 million in free cash flow during the third quarter. Setting new benchmarks in cannabis science, Aurora Cannabis Inc. (NASDAQ:ACB) operates a top-notch genetics and research facility in Canada. The business recently revealed that it has found a new genetic source of resistance to powdery mildew in cannabis sativa, which offers strong protection against this pathogen. The innovation, which is currently being used in its breeding program, provides a vital answer to a major problem facing the cannabis business globally. Overall, ACB ranks 10th on our list of the 10 Best Tobacco and Cigarette Stocks to Buy Now. While we acknowledge the potential of Tobacco and Cigarette companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ACB but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
